GGrantIndex
← Leaderboards

Kathleen E. Squires

University Of Southern California

$5,307,612
Attributed
$5,307,612
Total exposure
12
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $955.7K · FY200509
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$5,307,612 · 12

By mechanism

U01$5,016,163 · 2
M01$291,449 · 10

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHiv InfectionsResearch PersonnelRitonavirHuman SubjectAids TherapyHuman Therapy EvaluationProtease InhibitorResourcesBasePharmaceutical PreparationsPharmacokineticsLopinavir/RitonavirRandomizedSourceGrantFundingEfavirenzComputer Retrieval Of Information On Scientific Projects DatabasePatient Oriented ResearchUnited States National Institutes Of HealthInstitutionProdrugsLamivudine

Grant awards (17)

Quintiles Clinical Trial Unit for HIV/AIDS Clinical Trials Networks$886,623
U01 · FY2009 · AI · contact PI
Quintiles Clinical Trial Unit for HIV/AIDS Clinical Trials Networks$946,844
U01 · FY2008 · AI · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$8,292
M01 · FY2008 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$552
M01 · FY2008 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$51,576
M01 · FY2007 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$3,435
M01 · FY2007 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$6,060
M01 · FY2006 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$105,412
M01 · FY2005 · RR
ACTG A5039: AN OPEN-LABEL, NON-RANDOMIZED STUDY OF PHARMACOKINETIC INTERACTIONS$21,511
M01 · FY2005 · RR
A PHASE II STUDY OF THE PREDICTIVE VALUE OF PHARMACOKINETIC-ADJUSTED PHENOTYPIC$17,213
M01 · FY2005 · RR
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY,$2,149
M01 · FY2005 · RR
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON$34,396
M01 · FY2004 · RR
ACTG A5039: AN OPEN-LABEL, NON-RANDOMIZED STUDY$19,349
M01 · FY2004 · RR
A RANDOMIZED, COMPARATIVE STUDY OF LIPONAVIR/RITONAVIR$10,752
M01 · FY2004 · RR
A PHASE II STUDY OF PREDICTIVE VALUE OF PHARMACOKINETICS$10,752
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT (ACTU)$1,639,776
U01 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT (ACTU)$1,542,920
U01 · FY2002 · AI